HistoRx Announces First Clinical Diagnostic Use of AQUAÂ® Technology
BRANFORD, Conn., Nov. 12, 2010 /PRNewswire/ — HistoRx, Inc. (privately held), a diagnostics company, announced the launch and first commercial sale this week of clinical diagnostic assays based on AQUAÃ‚® technology. Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory service provider, is launching NexCourseÃ‚®(1) BCa by AQUA technology, a suite of breast cancer assays based on quantitative immunohistochemistry. NexCourse BCa by AQUA technology is:
- More reproducible than traditional IHC testing, for confidence in determining appropriate therapy
- Minimizes receptor status false-negative results by utilizing an objective, quantified score for protein expression that provides more accurate results; and
- Ideal for confirmatory testing of ER/PR/HER2 status prior to hormonal therapy, antibody-based therapy and/or chemotherapy when initial results are inconclusive or negative.
Genoptix and HistoRx signed a multi-year licensing agreement for AQUAÃ‚® technology and several diagnostic assays based on it in February 2010; the first commercial use announced today triggers a key milestone payment outlined in the agreement. Genoptix obtained exclusive commercial laboratory rights in the United States to develop and perform estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) assays using HistoRx’s proprietary technology. Misclassification of receptor status by IHC is common: several studies have shown that false-positive and false-negative ER/PR/HER2 results occur regularly in laboratories around the country and around the world. Inaccurate results may affect treatment decisions, excluding patients from use of potentially efficacious therapies or inappropriately subjecting patients to therapies known to cause serious adverse events.
“HistoRx is delighted to announce the first availability of AQUAÃ‚® technology for clinical diagnostics, and pleased that the breast cancer community will be the immediate beneficiaries of the quantification and reproducibility of measurement inherent in NexCourse BCa by AQUA technology,” said Rana K. Gupta, CEO of HistoRx. “Genoptix has gained the trust of community oncologists and their patients by offering high quality laboratory testing, and HistoRx couldn’t think of a more appropriate inaugural partner for commercialization of these assays.”
“Peer-reviewed literature shows that conventional IHC-based technology can misclassify ER/PR/HER2 receptor status,” said Mike Nerenberg, Senior Vice President and Chief Technology Officer at Genoptix. “AQUA technology is noted for its reproducible quantitation of protein biomarkers in tissue, and can therefore give oncologists confidence when determining the appropriate therapy for their breast cancer patients.”
AQUA technology quantifies tumor markers in designated areas of interest, an important component of the assessment of solid tumors for individual cancer patients.
About HistoRx, Inc.
HistoRx, Inc. is a leading developer of tissue-based diagnostic solutions to advance individualized patient care. The company’s products and services are based on proprietary analysis of tissue biomarkers using AQUAÃ‚® technology. AQUAÃ‚® technology is the only platform capable of precisely measuring protein biomarker concentration with sub-cellular resolution in tissue sections, enabling fully objective, standardized, reproducible, and automated analysis to guide drug development and therapeutic decision-making. HistoRx is commercializing a pipeline of proprietary diagnostic products targeting improved treatment decision-making and patient outcomes in cancer care. For more information, please visit www.historx.com.
About Genoptix, Inc.
Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix’s highly trained group of pathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its primary diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, and solid tumors. Founded in 1999, Genoptix completed its initial public offering in November 2007 and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.
(1) NexCourseÃ‚® is a registered trademark of Genoptix, Inc.
SOURCE HistoRx, Inc.